nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—Protein Kinase Inhibitors—Nilotinib—hematologic cancer	0.222	0.5	CiPCiCtD
Sirolimus—Protein Kinase Inhibitors—Ruxolitinib—hematologic cancer	0.222	0.5	CiPCiCtD
Sirolimus—FGF2—hematologic cancer	0.101	0.511	CbGaD
Sirolimus—MTOR—hematologic cancer	0.0826	0.417	CbGaD
Sirolimus—SLC47A1—Imatinib—hematologic cancer	0.026	0.143	CbGbCtD
Sirolimus—SLC47A1—Mitoxantrone—hematologic cancer	0.0207	0.113	CbGbCtD
Sirolimus—ABCB1—hematologic cancer	0.0142	0.0717	CbGaD
Sirolimus—ABCB1—Lenalidomide—hematologic cancer	0.00477	0.0262	CbGbCtD
Sirolimus—SLCO1B1—Irinotecan—hematologic cancer	0.00467	0.0256	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Ifosfamide—hematologic cancer	0.0046	0.0252	CbGbCtD
Sirolimus—CYP3A7—Ifosfamide—hematologic cancer	0.0046	0.0252	CbGbCtD
Sirolimus—CYP3A7—Imatinib—hematologic cancer	0.00439	0.0241	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Imatinib—hematologic cancer	0.00439	0.0241	CbGbCtD
Sirolimus—CYP3A5—Daunorubicin—hematologic cancer	0.0043	0.0236	CbGbCtD
Sirolimus—CYP3A5—Thalidomide—hematologic cancer	0.00392	0.0215	CbGbCtD
Sirolimus—CYP3A5—Teniposide—hematologic cancer	0.00374	0.0205	CbGbCtD
Sirolimus—CYP3A5—Ifosfamide—hematologic cancer	0.00345	0.0189	CbGbCtD
Sirolimus—CYP3A5—Imatinib—hematologic cancer	0.00329	0.0181	CbGbCtD
Sirolimus—CYP3A4—Bexarotene—hematologic cancer	0.00286	0.0157	CbGbCtD
Sirolimus—ABCB1—Daunorubicin—hematologic cancer	0.0028	0.0154	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Irinotecan—hematologic cancer	0.00274	0.015	CbGbCtD
Sirolimus—CYP3A7—Irinotecan—hematologic cancer	0.00274	0.015	CbGbCtD
Sirolimus—ABCB1—Alitretinoin—hematologic cancer	0.00274	0.015	CbGbCtD
Sirolimus—CYP3A4—Lomustine—hematologic cancer	0.00266	0.0146	CbGbCtD
Sirolimus—CYP3A4—Busulfan—hematologic cancer	0.00266	0.0146	CbGbCtD
Sirolimus—CYP3A5—Dasatinib—hematologic cancer	0.00265	0.0145	CbGbCtD
Sirolimus—SLCO1B1—Methotrexate—hematologic cancer	0.00247	0.0136	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Vincristine—hematologic cancer	0.0024	0.0132	CbGbCtD
Sirolimus—CYP3A7—Vincristine—hematologic cancer	0.0024	0.0132	CbGbCtD
Sirolimus—CYP3A4—Thiotepa—hematologic cancer	0.00237	0.013	CbGbCtD
Sirolimus—ABCB1—Imatinib—hematologic cancer	0.00214	0.0118	CbGbCtD
Sirolimus—CYP3A5—Irinotecan—hematologic cancer	0.00206	0.0113	CbGbCtD
Sirolimus—ABCB1—Nilotinib—hematologic cancer	0.00195	0.0107	CbGbCtD
Sirolimus—ABCB1—Vinorelbine—hematologic cancer	0.00193	0.0106	CbGbCtD
Sirolimus—CYP3A4—Methoxsalen—hematologic cancer	0.00184	0.0101	CbGbCtD
Sirolimus—CYP3A7—Dexamethasone—hematologic cancer	0.00181	0.00991	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Dexamethasone—hematologic cancer	0.00181	0.00991	CbGbCtD
Sirolimus—CYP3A5—Vincristine—hematologic cancer	0.0018	0.00987	CbGbCtD
Sirolimus—CYP3A4—Bortezomib—hematologic cancer	0.00175	0.00962	CbGbCtD
Sirolimus—ABCB1—Dasatinib—hematologic cancer	0.00172	0.00945	CbGbCtD
Sirolimus—ABCB1—Mitoxantrone—hematologic cancer	0.0017	0.00933	CbGbCtD
Sirolimus—CYP3A4—Daunorubicin—hematologic cancer	0.00168	0.0092	CbGbCtD
Sirolimus—EIF4E—hematopoietic system—hematologic cancer	0.00167	0.0959	CbGeAlD
Sirolimus—CYP3A5—Etoposide—hematologic cancer	0.00165	0.00904	CbGbCtD
Sirolimus—ABCB1—Betamethasone—hematologic cancer	0.00152	0.00832	CbGbCtD
Sirolimus—ABCB1—Gemcitabine—hematologic cancer	0.0015	0.00824	CbGbCtD
Sirolimus—ABCB1—Prednisolone—hematologic cancer	0.0015	0.00821	CbGbCtD
Sirolimus—CYP3A4—Cytarabine—hematologic cancer	0.00148	0.00811	CbGbCtD
Sirolimus—CYP3A4—Teniposide—hematologic cancer	0.00146	0.00799	CbGbCtD
Sirolimus—ABCB1—Prednisone—hematologic cancer	0.00141	0.00775	CbGbCtD
Sirolimus—CYP3A5—Dexamethasone—hematologic cancer	0.00135	0.00743	CbGbCtD
Sirolimus—CYP3A4—Ifosfamide—hematologic cancer	0.00134	0.00738	CbGbCtD
Sirolimus—ABCB1—Irinotecan—hematologic cancer	0.00134	0.00735	CbGbCtD
Sirolimus—CYP3A4—Imatinib—hematologic cancer	0.00128	0.00705	CbGbCtD
Sirolimus—EIF4E—gonad—hematologic cancer	0.00127	0.0729	CbGeAlD
Sirolimus—CYP3A4—Ruxolitinib—hematologic cancer	0.00121	0.00664	CbGbCtD
Sirolimus—ABCB1—Vinblastine—hematologic cancer	0.00119	0.00653	CbGbCtD
Sirolimus—ABCB1—Vincristine—hematologic cancer	0.00117	0.00642	CbGbCtD
Sirolimus—CYP3A4—Nilotinib—hematologic cancer	0.00117	0.0064	CbGbCtD
Sirolimus—CYP3A4—Vinorelbine—hematologic cancer	0.00116	0.00635	CbGbCtD
Sirolimus—EIF4E—blood—hematologic cancer	0.00111	0.0635	CbGeAlD
Sirolimus—ABCB1—Cisplatin—hematologic cancer	0.00109	0.00599	CbGbCtD
Sirolimus—ABCB1—Etoposide—hematologic cancer	0.00107	0.00588	CbGbCtD
Sirolimus—CYP3A4—Triamcinolone—hematologic cancer	0.00106	0.00581	CbGbCtD
Sirolimus—CYP3A4—Dasatinib—hematologic cancer	0.00103	0.00566	CbGbCtD
Sirolimus—CYP3A4—Mitoxantrone—hematologic cancer	0.00102	0.00559	CbGbCtD
Sirolimus—EIF4E—lung—hematologic cancer	0.00097	0.0557	CbGeAlD
Sirolimus—EIF4E—testis—hematologic cancer	0.000915	0.0526	CbGeAlD
Sirolimus—CYP3A4—Betamethasone—hematologic cancer	0.000908	0.00498	CbGbCtD
Sirolimus—CYP3A4—Prednisolone—hematologic cancer	0.000896	0.00492	CbGbCtD
Sirolimus—ABCB1—Dexamethasone—hematologic cancer	0.000882	0.00484	CbGbCtD
Sirolimus—CYP3A4—Prednisone—hematologic cancer	0.000846	0.00464	CbGbCtD
Sirolimus—CYP3A4—Irinotecan—hematologic cancer	0.000802	0.0044	CbGbCtD
Sirolimus—ABCB1—Doxorubicin—hematologic cancer	0.000732	0.00401	CbGbCtD
Sirolimus—CYP3A4—Vinblastine—hematologic cancer	0.000713	0.00391	CbGbCtD
Sirolimus—ABCB1—Methotrexate—hematologic cancer	0.000709	0.00389	CbGbCtD
Sirolimus—CYP3A4—Vincristine—hematologic cancer	0.000701	0.00385	CbGbCtD
Sirolimus—MTOR—hematopoietic system—hematologic cancer	0.000646	0.0371	CbGeAlD
Sirolimus—CYP3A4—Etoposide—hematologic cancer	0.000643	0.00353	CbGbCtD
Sirolimus—FGF2—lung—hematologic cancer	0.000591	0.034	CbGeAlD
Sirolimus—FKBP1A—hematopoietic system—hematologic cancer	0.000581	0.0334	CbGeAlD
Sirolimus—FGF2—testis—hematologic cancer	0.000558	0.0321	CbGeAlD
Sirolimus—CYP3A4—Dexamethasone—hematologic cancer	0.000528	0.0029	CbGbCtD
Sirolimus—SLC47A1—hematopoietic system—hematologic cancer	0.000499	0.0287	CbGeAlD
Sirolimus—SLCO1B1—hematopoietic system—hematologic cancer	0.000493	0.0283	CbGeAlD
Sirolimus—MTOR—gonad—hematologic cancer	0.000491	0.0282	CbGeAlD
Sirolimus—Pimecrolimus—MTOR—hematologic cancer	0.000465	0.278	CrCbGaD
Sirolimus—Everolimus—MTOR—hematologic cancer	0.000465	0.278	CrCbGaD
Sirolimus—FKBP1A—gonad—hematologic cancer	0.000442	0.0254	CbGeAlD
Sirolimus—CYP3A4—Doxorubicin—hematologic cancer	0.000438	0.0024	CbGbCtD
Sirolimus—MTOR—blood—hematologic cancer	0.000428	0.0246	CbGeAlD
Sirolimus—MTOR—bone marrow—hematologic cancer	0.000414	0.0238	CbGeAlD
Sirolimus—FGF2—lymph node—hematologic cancer	0.000404	0.0232	CbGeAlD
Sirolimus—FKBP1A—blood—hematologic cancer	0.000385	0.0221	CbGeAlD
Sirolimus—SLC47A1—gonad—hematologic cancer	0.00038	0.0218	CbGeAlD
Sirolimus—MTOR—lung—hematologic cancer	0.000375	0.0216	CbGeAlD
Sirolimus—FKBP1A—bone marrow—hematologic cancer	0.000372	0.0214	CbGeAlD
Sirolimus—MTOR—testis—hematologic cancer	0.000354	0.0203	CbGeAlD
Sirolimus—FKBP1A—lung—hematologic cancer	0.000337	0.0194	CbGeAlD
Sirolimus—SLC47A1—blood—hematologic cancer	0.000331	0.019	CbGeAlD
Sirolimus—SLCO1B1—blood—hematologic cancer	0.000327	0.0188	CbGeAlD
Sirolimus—FKBP1A—testis—hematologic cancer	0.000318	0.0183	CbGeAlD
Sirolimus—Temsirolimus—MTOR—hematologic cancer	0.000314	0.188	CrCbGaD
Sirolimus—SLC47A1—lung—hematologic cancer	0.00029	0.0167	CbGeAlD
Sirolimus—Tacrolimus—MTOR—hematologic cancer	0.000277	0.165	CrCbGaD
Sirolimus—SLC47A1—testis—hematologic cancer	0.000274	0.0157	CbGeAlD
Sirolimus—MTOR—lymph node—hematologic cancer	0.000257	0.0147	CbGeAlD
Sirolimus—CYP3A5—hematopoietic system—hematologic cancer	0.000253	0.0145	CbGeAlD
Sirolimus—FKBP1A—lymph node—hematologic cancer	0.000231	0.0133	CbGeAlD
Sirolimus—SLC47A1—lymph node—hematologic cancer	0.000198	0.0114	CbGeAlD
Sirolimus—CYP3A4—hematopoietic system—hematologic cancer	0.00019	0.0109	CbGeAlD
Sirolimus—CYP3A5—blood—hematologic cancer	0.000168	0.00963	CbGeAlD
Sirolimus—CYP3A5—lung—hematologic cancer	0.000147	0.00844	CbGeAlD
Sirolimus—ABCB1—hematopoietic system—hematologic cancer	0.000134	0.00772	CbGeAlD
Sirolimus—CYP3A4—blood—hematologic cancer	0.000126	0.00723	CbGeAlD
Sirolimus—ABCB1—gonad—hematologic cancer	0.000102	0.00587	CbGeAlD
Sirolimus—ABCB1—blood—hematologic cancer	8.9e-05	0.00512	CbGeAlD
Sirolimus—ABCB1—bone marrow—hematologic cancer	8.62e-05	0.00495	CbGeAlD
Sirolimus—ABCB1—lung—hematologic cancer	7.81e-05	0.00448	CbGeAlD
Sirolimus—ABCB1—testis—hematologic cancer	7.37e-05	0.00423	CbGeAlD
Sirolimus—Temsirolimus—ABCB1—hematologic cancer	5.4e-05	0.0323	CrCbGaD
Sirolimus—ABCB1—lymph node—hematologic cancer	5.34e-05	0.00307	CbGeAlD
Sirolimus—Tacrolimus—ALB—hematologic cancer	4.98e-05	0.0298	CrCbGaD
Sirolimus—Tacrolimus—ABCB1—hematologic cancer	4.76e-05	0.0284	CrCbGaD
Sirolimus—Gastrointestinal disorder—Betamethasone—hematologic cancer	4.35e-06	4.66e-05	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Dexamethasone—hematologic cancer	4.35e-06	4.66e-05	CcSEcCtD
Sirolimus—Back pain—Methotrexate—hematologic cancer	4.35e-06	4.65e-05	CcSEcCtD
Sirolimus—Chills—Epirubicin—hematologic cancer	4.33e-06	4.64e-05	CcSEcCtD
Sirolimus—Pruritus—Etoposide—hematologic cancer	4.33e-06	4.64e-05	CcSEcCtD
Sirolimus—Shock—Prednisone—hematologic cancer	4.32e-06	4.62e-05	CcSEcCtD
Sirolimus—Pain—Dexamethasone—hematologic cancer	4.31e-06	4.61e-05	CcSEcCtD
Sirolimus—Pain—Betamethasone—hematologic cancer	4.31e-06	4.61e-05	CcSEcCtD
Sirolimus—Visual impairment—Doxorubicin—hematologic cancer	4.31e-06	4.61e-05	CcSEcCtD
Sirolimus—Nervous system disorder—Prednisone—hematologic cancer	4.3e-06	4.61e-05	CcSEcCtD
Sirolimus—Tachycardia—Prednisone—hematologic cancer	4.28e-06	4.58e-05	CcSEcCtD
Sirolimus—Skin disorder—Prednisone—hematologic cancer	4.26e-06	4.56e-05	CcSEcCtD
Sirolimus—Nausea—Gemcitabine—hematologic cancer	4.26e-06	4.56e-05	CcSEcCtD
Sirolimus—Vomiting—Cisplatin—hematologic cancer	4.25e-06	4.55e-05	CcSEcCtD
Sirolimus—Hyperhidrosis—Prednisone—hematologic cancer	4.24e-06	4.54e-05	CcSEcCtD
Sirolimus—Rash—Cisplatin—hematologic cancer	4.21e-06	4.51e-05	CcSEcCtD
Sirolimus—Dermatitis—Cisplatin—hematologic cancer	4.21e-06	4.51e-05	CcSEcCtD
Sirolimus—Malnutrition—Epirubicin—hematologic cancer	4.21e-06	4.5e-05	CcSEcCtD
Sirolimus—Diarrhoea—Etoposide—hematologic cancer	4.19e-06	4.48e-05	CcSEcCtD
Sirolimus—Anorexia—Prednisone—hematologic cancer	4.18e-06	4.48e-05	CcSEcCtD
Sirolimus—Ill-defined disorder—Methotrexate—hematologic cancer	4.17e-06	4.46e-05	CcSEcCtD
Sirolimus—Tinnitus—Doxorubicin—hematologic cancer	4.17e-06	4.46e-05	CcSEcCtD
Sirolimus—Anaemia—Methotrexate—hematologic cancer	4.15e-06	4.44e-05	CcSEcCtD
Sirolimus—Feeling abnormal—Betamethasone—hematologic cancer	4.15e-06	4.44e-05	CcSEcCtD
Sirolimus—Feeling abnormal—Dexamethasone—hematologic cancer	4.15e-06	4.44e-05	CcSEcCtD
Sirolimus—Cardiac disorder—Doxorubicin—hematologic cancer	4.15e-06	4.44e-05	CcSEcCtD
Sirolimus—Flatulence—Epirubicin—hematologic cancer	4.14e-06	4.43e-05	CcSEcCtD
Sirolimus—Tension—Epirubicin—hematologic cancer	4.13e-06	4.42e-05	CcSEcCtD
Sirolimus—Gastrointestinal pain—Dexamethasone—hematologic cancer	4.12e-06	4.41e-05	CcSEcCtD
Sirolimus—Gastrointestinal pain—Betamethasone—hematologic cancer	4.12e-06	4.41e-05	CcSEcCtD
Sirolimus—Hypersensitivity—Triamcinolone—hematologic cancer	4.09e-06	4.38e-05	CcSEcCtD
Sirolimus—Nervousness—Epirubicin—hematologic cancer	4.08e-06	4.37e-05	CcSEcCtD
Sirolimus—Back pain—Epirubicin—hematologic cancer	4.07e-06	4.35e-05	CcSEcCtD
Sirolimus—Angiopathy—Doxorubicin—hematologic cancer	4.06e-06	4.34e-05	CcSEcCtD
Sirolimus—Malaise—Methotrexate—hematologic cancer	4.05e-06	4.34e-05	CcSEcCtD
Sirolimus—Dizziness—Etoposide—hematologic cancer	4.05e-06	4.33e-05	CcSEcCtD
Sirolimus—Muscle spasms—Epirubicin—hematologic cancer	4.04e-06	4.33e-05	CcSEcCtD
Sirolimus—Immune system disorder—Doxorubicin—hematologic cancer	4.04e-06	4.32e-05	CcSEcCtD
Sirolimus—Mediastinal disorder—Doxorubicin—hematologic cancer	4.03e-06	4.31e-05	CcSEcCtD
Sirolimus—Leukopenia—Methotrexate—hematologic cancer	4.02e-06	4.3e-05	CcSEcCtD
Sirolimus—Chills—Doxorubicin—hematologic cancer	4.01e-06	4.29e-05	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Prednisone—hematologic cancer	4e-06	4.28e-05	CcSEcCtD
Sirolimus—Dizziness—Prednisolone—hematologic cancer	3.99e-06	4.27e-05	CcSEcCtD
Sirolimus—Asthenia—Triamcinolone—hematologic cancer	3.98e-06	4.26e-05	CcSEcCtD
Sirolimus—Abdominal pain—Dexamethasone—hematologic cancer	3.98e-06	4.26e-05	CcSEcCtD
Sirolimus—Body temperature increased—Betamethasone—hematologic cancer	3.98e-06	4.26e-05	CcSEcCtD
Sirolimus—Abdominal pain—Betamethasone—hematologic cancer	3.98e-06	4.26e-05	CcSEcCtD
Sirolimus—Body temperature increased—Dexamethasone—hematologic cancer	3.98e-06	4.26e-05	CcSEcCtD
Sirolimus—Nausea—Cisplatin—hematologic cancer	3.97e-06	4.25e-05	CcSEcCtD
Sirolimus—Insomnia—Prednisone—hematologic cancer	3.97e-06	4.25e-05	CcSEcCtD
Sirolimus—Paraesthesia—Prednisone—hematologic cancer	3.94e-06	4.22e-05	CcSEcCtD
Sirolimus—Pruritus—Triamcinolone—hematologic cancer	3.93e-06	4.2e-05	CcSEcCtD
Sirolimus—Cough—Methotrexate—hematologic cancer	3.92e-06	4.2e-05	CcSEcCtD
Sirolimus—Ill-defined disorder—Epirubicin—hematologic cancer	3.9e-06	4.18e-05	CcSEcCtD
Sirolimus—Vomiting—Etoposide—hematologic cancer	3.89e-06	4.17e-05	CcSEcCtD
Sirolimus—Malnutrition—Doxorubicin—hematologic cancer	3.89e-06	4.16e-05	CcSEcCtD
Sirolimus—Anaemia—Epirubicin—hematologic cancer	3.89e-06	4.16e-05	CcSEcCtD
Sirolimus—Agitation—Epirubicin—hematologic cancer	3.86e-06	4.14e-05	CcSEcCtD
Sirolimus—Dyspepsia—Prednisone—hematologic cancer	3.86e-06	4.13e-05	CcSEcCtD
Sirolimus—Rash—Etoposide—hematologic cancer	3.86e-06	4.13e-05	CcSEcCtD
Sirolimus—Dermatitis—Etoposide—hematologic cancer	3.86e-06	4.13e-05	CcSEcCtD
Sirolimus—Headache—Etoposide—hematologic cancer	3.84e-06	4.1e-05	CcSEcCtD
Sirolimus—Flatulence—Doxorubicin—hematologic cancer	3.83e-06	4.1e-05	CcSEcCtD
Sirolimus—Chest pain—Methotrexate—hematologic cancer	3.83e-06	4.09e-05	CcSEcCtD
Sirolimus—Arthralgia—Methotrexate—hematologic cancer	3.83e-06	4.09e-05	CcSEcCtD
Sirolimus—Myalgia—Methotrexate—hematologic cancer	3.83e-06	4.09e-05	CcSEcCtD
Sirolimus—Tension—Doxorubicin—hematologic cancer	3.82e-06	4.09e-05	CcSEcCtD
Sirolimus—Decreased appetite—Prednisone—hematologic cancer	3.82e-06	4.08e-05	CcSEcCtD
Sirolimus—Rash—Prednisolone—hematologic cancer	3.81e-06	4.07e-05	CcSEcCtD
Sirolimus—Dermatitis—Prednisolone—hematologic cancer	3.8e-06	4.07e-05	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	3.8e-06	4.07e-05	CcSEcCtD
Sirolimus—Malaise—Epirubicin—hematologic cancer	3.79e-06	4.06e-05	CcSEcCtD
Sirolimus—Headache—Prednisolone—hematologic cancer	3.78e-06	4.05e-05	CcSEcCtD
Sirolimus—Discomfort—Methotrexate—hematologic cancer	3.78e-06	4.05e-05	CcSEcCtD
Sirolimus—Nervousness—Doxorubicin—hematologic cancer	3.78e-06	4.04e-05	CcSEcCtD
Sirolimus—Syncope—Epirubicin—hematologic cancer	3.77e-06	4.04e-05	CcSEcCtD
Sirolimus—Leukopenia—Epirubicin—hematologic cancer	3.76e-06	4.03e-05	CcSEcCtD
Sirolimus—Back pain—Doxorubicin—hematologic cancer	3.76e-06	4.03e-05	CcSEcCtD
Sirolimus—Constipation—Prednisone—hematologic cancer	3.75e-06	4.02e-05	CcSEcCtD
Sirolimus—Muscle spasms—Doxorubicin—hematologic cancer	3.74e-06	4e-05	CcSEcCtD
Sirolimus—Palpitations—Epirubicin—hematologic cancer	3.72e-06	3.98e-05	CcSEcCtD
Sirolimus—Confusional state—Methotrexate—hematologic cancer	3.7e-06	3.96e-05	CcSEcCtD
Sirolimus—Loss of consciousness—Epirubicin—hematologic cancer	3.7e-06	3.96e-05	CcSEcCtD
Sirolimus—Dizziness—Triamcinolone—hematologic cancer	3.67e-06	3.93e-05	CcSEcCtD
Sirolimus—Cough—Epirubicin—hematologic cancer	3.67e-06	3.93e-05	CcSEcCtD
Sirolimus—Anaphylactic shock—Methotrexate—hematologic cancer	3.67e-06	3.92e-05	CcSEcCtD
Sirolimus—Infection—Methotrexate—hematologic cancer	3.64e-06	3.9e-05	CcSEcCtD
Sirolimus—Nausea—Etoposide—hematologic cancer	3.64e-06	3.89e-05	CcSEcCtD
Sirolimus—Hypertension—Epirubicin—hematologic cancer	3.63e-06	3.89e-05	CcSEcCtD
Sirolimus—Feeling abnormal—Prednisone—hematologic cancer	3.62e-06	3.87e-05	CcSEcCtD
Sirolimus—Asthenia—Betamethasone—hematologic cancer	3.62e-06	3.87e-05	CcSEcCtD
Sirolimus—Asthenia—Dexamethasone—hematologic cancer	3.62e-06	3.87e-05	CcSEcCtD
Sirolimus—Ill-defined disorder—Doxorubicin—hematologic cancer	3.61e-06	3.86e-05	CcSEcCtD
Sirolimus—Nervous system disorder—Methotrexate—hematologic cancer	3.6e-06	3.85e-05	CcSEcCtD
Sirolimus—Anaemia—Doxorubicin—hematologic cancer	3.6e-06	3.85e-05	CcSEcCtD
Sirolimus—Thrombocytopenia—Methotrexate—hematologic cancer	3.59e-06	3.84e-05	CcSEcCtD
Sirolimus—Gastrointestinal pain—Prednisone—hematologic cancer	3.59e-06	3.84e-05	CcSEcCtD
Sirolimus—Nausea—Prednisolone—hematologic cancer	3.59e-06	3.84e-05	CcSEcCtD
Sirolimus—Chest pain—Epirubicin—hematologic cancer	3.58e-06	3.83e-05	CcSEcCtD
Sirolimus—Myalgia—Epirubicin—hematologic cancer	3.58e-06	3.83e-05	CcSEcCtD
Sirolimus—Arthralgia—Epirubicin—hematologic cancer	3.58e-06	3.83e-05	CcSEcCtD
Sirolimus—Agitation—Doxorubicin—hematologic cancer	3.58e-06	3.83e-05	CcSEcCtD
Sirolimus—Anxiety—Epirubicin—hematologic cancer	3.57e-06	3.82e-05	CcSEcCtD
Sirolimus—Pruritus—Betamethasone—hematologic cancer	3.57e-06	3.82e-05	CcSEcCtD
Sirolimus—Pruritus—Dexamethasone—hematologic cancer	3.57e-06	3.82e-05	CcSEcCtD
Sirolimus—Skin disorder—Methotrexate—hematologic cancer	3.56e-06	3.81e-05	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	3.56e-06	3.81e-05	CcSEcCtD
Sirolimus—Hyperhidrosis—Methotrexate—hematologic cancer	3.55e-06	3.79e-05	CcSEcCtD
Sirolimus—Discomfort—Epirubicin—hematologic cancer	3.54e-06	3.79e-05	CcSEcCtD
Sirolimus—Vomiting—Triamcinolone—hematologic cancer	3.53e-06	3.78e-05	CcSEcCtD
Sirolimus—Malaise—Doxorubicin—hematologic cancer	3.51e-06	3.76e-05	CcSEcCtD
Sirolimus—Rash—Triamcinolone—hematologic cancer	3.5e-06	3.75e-05	CcSEcCtD
Sirolimus—Dermatitis—Triamcinolone—hematologic cancer	3.5e-06	3.74e-05	CcSEcCtD
Sirolimus—Anorexia—Methotrexate—hematologic cancer	3.5e-06	3.74e-05	CcSEcCtD
Sirolimus—Syncope—Doxorubicin—hematologic cancer	3.49e-06	3.73e-05	CcSEcCtD
Sirolimus—Leukopenia—Doxorubicin—hematologic cancer	3.48e-06	3.73e-05	CcSEcCtD
Sirolimus—Headache—Triamcinolone—hematologic cancer	3.48e-06	3.72e-05	CcSEcCtD
Sirolimus—Abdominal pain—Prednisone—hematologic cancer	3.47e-06	3.71e-05	CcSEcCtD
Sirolimus—Body temperature increased—Prednisone—hematologic cancer	3.47e-06	3.71e-05	CcSEcCtD
Sirolimus—Confusional state—Epirubicin—hematologic cancer	3.46e-06	3.7e-05	CcSEcCtD
Sirolimus—Diarrhoea—Dexamethasone—hematologic cancer	3.45e-06	3.69e-05	CcSEcCtD
Sirolimus—Diarrhoea—Betamethasone—hematologic cancer	3.45e-06	3.69e-05	CcSEcCtD
Sirolimus—Palpitations—Doxorubicin—hematologic cancer	3.44e-06	3.68e-05	CcSEcCtD
Sirolimus—Anaphylactic shock—Epirubicin—hematologic cancer	3.43e-06	3.67e-05	CcSEcCtD
Sirolimus—Oedema—Epirubicin—hematologic cancer	3.43e-06	3.67e-05	CcSEcCtD
Sirolimus—Hypotension—Methotrexate—hematologic cancer	3.43e-06	3.67e-05	CcSEcCtD
Sirolimus—Loss of consciousness—Doxorubicin—hematologic cancer	3.42e-06	3.66e-05	CcSEcCtD
Sirolimus—Infection—Epirubicin—hematologic cancer	3.41e-06	3.65e-05	CcSEcCtD
Sirolimus—Cough—Doxorubicin—hematologic cancer	3.4e-06	3.63e-05	CcSEcCtD
Sirolimus—Shock—Epirubicin—hematologic cancer	3.38e-06	3.61e-05	CcSEcCtD
Sirolimus—Nervous system disorder—Epirubicin—hematologic cancer	3.37e-06	3.6e-05	CcSEcCtD
Sirolimus—Thrombocytopenia—Epirubicin—hematologic cancer	3.36e-06	3.6e-05	CcSEcCtD
Sirolimus—Hypertension—Doxorubicin—hematologic cancer	3.36e-06	3.6e-05	CcSEcCtD
Sirolimus—Tachycardia—Epirubicin—hematologic cancer	3.35e-06	3.58e-05	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Methotrexate—hematologic cancer	3.34e-06	3.58e-05	CcSEcCtD
Sirolimus—Skin disorder—Epirubicin—hematologic cancer	3.33e-06	3.57e-05	CcSEcCtD
Sirolimus—Dizziness—Betamethasone—hematologic cancer	3.33e-06	3.57e-05	CcSEcCtD
Sirolimus—Dizziness—Dexamethasone—hematologic cancer	3.33e-06	3.57e-05	CcSEcCtD
Sirolimus—Hyperhidrosis—Epirubicin—hematologic cancer	3.32e-06	3.55e-05	CcSEcCtD
Sirolimus—Insomnia—Methotrexate—hematologic cancer	3.32e-06	3.55e-05	CcSEcCtD
Sirolimus—Myalgia—Doxorubicin—hematologic cancer	3.31e-06	3.55e-05	CcSEcCtD
Sirolimus—Chest pain—Doxorubicin—hematologic cancer	3.31e-06	3.55e-05	CcSEcCtD
Sirolimus—Arthralgia—Doxorubicin—hematologic cancer	3.31e-06	3.55e-05	CcSEcCtD
Sirolimus—Anxiety—Doxorubicin—hematologic cancer	3.3e-06	3.53e-05	CcSEcCtD
Sirolimus—Nausea—Triamcinolone—hematologic cancer	3.3e-06	3.53e-05	CcSEcCtD
Sirolimus—Paraesthesia—Methotrexate—hematologic cancer	3.29e-06	3.52e-05	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	3.29e-06	3.52e-05	CcSEcCtD
Sirolimus—Discomfort—Doxorubicin—hematologic cancer	3.27e-06	3.5e-05	CcSEcCtD
Sirolimus—Anorexia—Epirubicin—hematologic cancer	3.27e-06	3.5e-05	CcSEcCtD
Sirolimus—Dyspnoea—Methotrexate—hematologic cancer	3.27e-06	3.5e-05	CcSEcCtD
Sirolimus—Somnolence—Methotrexate—hematologic cancer	3.26e-06	3.49e-05	CcSEcCtD
Sirolimus—Hypersensitivity—Prednisone—hematologic cancer	3.23e-06	3.46e-05	CcSEcCtD
Sirolimus—Dyspepsia—Methotrexate—hematologic cancer	3.23e-06	3.45e-05	CcSEcCtD
Sirolimus—Hypotension—Epirubicin—hematologic cancer	3.21e-06	3.43e-05	CcSEcCtD
Sirolimus—Vomiting—Betamethasone—hematologic cancer	3.2e-06	3.43e-05	CcSEcCtD
Sirolimus—Vomiting—Dexamethasone—hematologic cancer	3.2e-06	3.43e-05	CcSEcCtD
Sirolimus—Confusional state—Doxorubicin—hematologic cancer	3.2e-06	3.43e-05	CcSEcCtD
Sirolimus—Decreased appetite—Methotrexate—hematologic cancer	3.19e-06	3.41e-05	CcSEcCtD
Sirolimus—Rash—Dexamethasone—hematologic cancer	3.18e-06	3.4e-05	CcSEcCtD
Sirolimus—Rash—Betamethasone—hematologic cancer	3.18e-06	3.4e-05	CcSEcCtD
Sirolimus—Anaphylactic shock—Doxorubicin—hematologic cancer	3.18e-06	3.4e-05	CcSEcCtD
Sirolimus—Oedema—Doxorubicin—hematologic cancer	3.18e-06	3.4e-05	CcSEcCtD
Sirolimus—Dermatitis—Dexamethasone—hematologic cancer	3.17e-06	3.4e-05	CcSEcCtD
Sirolimus—Dermatitis—Betamethasone—hematologic cancer	3.17e-06	3.4e-05	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Methotrexate—hematologic cancer	3.17e-06	3.39e-05	CcSEcCtD
Sirolimus—Headache—Dexamethasone—hematologic cancer	3.16e-06	3.38e-05	CcSEcCtD
Sirolimus—Headache—Betamethasone—hematologic cancer	3.16e-06	3.38e-05	CcSEcCtD
Sirolimus—Infection—Doxorubicin—hematologic cancer	3.16e-06	3.38e-05	CcSEcCtD
Sirolimus—Asthenia—Prednisone—hematologic cancer	3.15e-06	3.37e-05	CcSEcCtD
Sirolimus—Pain—Methotrexate—hematologic cancer	3.14e-06	3.36e-05	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Epirubicin—hematologic cancer	3.13e-06	3.35e-05	CcSEcCtD
Sirolimus—Shock—Doxorubicin—hematologic cancer	3.12e-06	3.34e-05	CcSEcCtD
Sirolimus—Nervous system disorder—Doxorubicin—hematologic cancer	3.11e-06	3.33e-05	CcSEcCtD
Sirolimus—Thrombocytopenia—Doxorubicin—hematologic cancer	3.11e-06	3.33e-05	CcSEcCtD
Sirolimus—Pruritus—Prednisone—hematologic cancer	3.11e-06	3.32e-05	CcSEcCtD
Sirolimus—Insomnia—Epirubicin—hematologic cancer	3.1e-06	3.32e-05	CcSEcCtD
Sirolimus—Tachycardia—Doxorubicin—hematologic cancer	3.1e-06	3.32e-05	CcSEcCtD
Sirolimus—Skin disorder—Doxorubicin—hematologic cancer	3.08e-06	3.3e-05	CcSEcCtD
Sirolimus—Paraesthesia—Epirubicin—hematologic cancer	3.08e-06	3.3e-05	CcSEcCtD
Sirolimus—Hyperhidrosis—Doxorubicin—hematologic cancer	3.07e-06	3.29e-05	CcSEcCtD
Sirolimus—Dyspnoea—Epirubicin—hematologic cancer	3.06e-06	3.27e-05	CcSEcCtD
Sirolimus—Somnolence—Epirubicin—hematologic cancer	3.05e-06	3.27e-05	CcSEcCtD
Sirolimus—Anorexia—Doxorubicin—hematologic cancer	3.03e-06	3.24e-05	CcSEcCtD
Sirolimus—Feeling abnormal—Methotrexate—hematologic cancer	3.02e-06	3.23e-05	CcSEcCtD
Sirolimus—Dyspepsia—Epirubicin—hematologic cancer	3.02e-06	3.23e-05	CcSEcCtD
Sirolimus—Diarrhoea—Prednisone—hematologic cancer	3e-06	3.21e-05	CcSEcCtD
Sirolimus—Gastrointestinal pain—Methotrexate—hematologic cancer	3e-06	3.21e-05	CcSEcCtD
Sirolimus—Nausea—Betamethasone—hematologic cancer	2.99e-06	3.2e-05	CcSEcCtD
Sirolimus—Nausea—Dexamethasone—hematologic cancer	2.99e-06	3.2e-05	CcSEcCtD
Sirolimus—Decreased appetite—Epirubicin—hematologic cancer	2.98e-06	3.19e-05	CcSEcCtD
Sirolimus—Hypotension—Doxorubicin—hematologic cancer	2.97e-06	3.18e-05	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Epirubicin—hematologic cancer	2.96e-06	3.17e-05	CcSEcCtD
Sirolimus—Pain—Epirubicin—hematologic cancer	2.94e-06	3.14e-05	CcSEcCtD
Sirolimus—Constipation—Epirubicin—hematologic cancer	2.94e-06	3.14e-05	CcSEcCtD
Sirolimus—Dizziness—Prednisone—hematologic cancer	2.9e-06	3.11e-05	CcSEcCtD
Sirolimus—Abdominal pain—Methotrexate—hematologic cancer	2.9e-06	3.1e-05	CcSEcCtD
Sirolimus—Body temperature increased—Methotrexate—hematologic cancer	2.9e-06	3.1e-05	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	2.89e-06	3.1e-05	CcSEcCtD
Sirolimus—Insomnia—Doxorubicin—hematologic cancer	2.87e-06	3.07e-05	CcSEcCtD
Sirolimus—Paraesthesia—Doxorubicin—hematologic cancer	2.85e-06	3.05e-05	CcSEcCtD
Sirolimus—Dyspnoea—Doxorubicin—hematologic cancer	2.83e-06	3.03e-05	CcSEcCtD
Sirolimus—Feeling abnormal—Epirubicin—hematologic cancer	2.83e-06	3.03e-05	CcSEcCtD
Sirolimus—Somnolence—Doxorubicin—hematologic cancer	2.82e-06	3.02e-05	CcSEcCtD
Sirolimus—Gastrointestinal pain—Epirubicin—hematologic cancer	2.81e-06	3e-05	CcSEcCtD
Sirolimus—Dyspepsia—Doxorubicin—hematologic cancer	2.8e-06	2.99e-05	CcSEcCtD
Sirolimus—Vomiting—Prednisone—hematologic cancer	2.79e-06	2.99e-05	CcSEcCtD
Sirolimus—Rash—Prednisone—hematologic cancer	2.77e-06	2.96e-05	CcSEcCtD
Sirolimus—Dermatitis—Prednisone—hematologic cancer	2.76e-06	2.96e-05	CcSEcCtD
Sirolimus—Decreased appetite—Doxorubicin—hematologic cancer	2.76e-06	2.95e-05	CcSEcCtD
Sirolimus—Headache—Prednisone—hematologic cancer	2.75e-06	2.94e-05	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.74e-06	2.93e-05	CcSEcCtD
Sirolimus—Constipation—Doxorubicin—hematologic cancer	2.72e-06	2.91e-05	CcSEcCtD
Sirolimus—Pain—Doxorubicin—hematologic cancer	2.72e-06	2.91e-05	CcSEcCtD
Sirolimus—Body temperature increased—Epirubicin—hematologic cancer	2.71e-06	2.9e-05	CcSEcCtD
Sirolimus—Abdominal pain—Epirubicin—hematologic cancer	2.71e-06	2.9e-05	CcSEcCtD
Sirolimus—Hypersensitivity—Methotrexate—hematologic cancer	2.7e-06	2.89e-05	CcSEcCtD
Sirolimus—Asthenia—Methotrexate—hematologic cancer	2.63e-06	2.82e-05	CcSEcCtD
Sirolimus—Feeling abnormal—Doxorubicin—hematologic cancer	2.62e-06	2.8e-05	CcSEcCtD
Sirolimus—Nausea—Prednisone—hematologic cancer	2.61e-06	2.79e-05	CcSEcCtD
Sirolimus—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.6e-06	2.78e-05	CcSEcCtD
Sirolimus—Pruritus—Methotrexate—hematologic cancer	2.59e-06	2.78e-05	CcSEcCtD
Sirolimus—Hypersensitivity—Epirubicin—hematologic cancer	2.53e-06	2.71e-05	CcSEcCtD
Sirolimus—Body temperature increased—Doxorubicin—hematologic cancer	2.51e-06	2.69e-05	CcSEcCtD
Sirolimus—Abdominal pain—Doxorubicin—hematologic cancer	2.51e-06	2.69e-05	CcSEcCtD
Sirolimus—Diarrhoea—Methotrexate—hematologic cancer	2.51e-06	2.69e-05	CcSEcCtD
Sirolimus—Asthenia—Epirubicin—hematologic cancer	2.46e-06	2.64e-05	CcSEcCtD
Sirolimus—Pruritus—Epirubicin—hematologic cancer	2.43e-06	2.6e-05	CcSEcCtD
Sirolimus—Dizziness—Methotrexate—hematologic cancer	2.43e-06	2.6e-05	CcSEcCtD
Sirolimus—Diarrhoea—Epirubicin—hematologic cancer	2.35e-06	2.51e-05	CcSEcCtD
Sirolimus—Hypersensitivity—Doxorubicin—hematologic cancer	2.34e-06	2.5e-05	CcSEcCtD
Sirolimus—Vomiting—Methotrexate—hematologic cancer	2.33e-06	2.5e-05	CcSEcCtD
Sirolimus—Rash—Methotrexate—hematologic cancer	2.31e-06	2.47e-05	CcSEcCtD
Sirolimus—Dermatitis—Methotrexate—hematologic cancer	2.31e-06	2.47e-05	CcSEcCtD
Sirolimus—Headache—Methotrexate—hematologic cancer	2.3e-06	2.46e-05	CcSEcCtD
Sirolimus—Asthenia—Doxorubicin—hematologic cancer	2.28e-06	2.44e-05	CcSEcCtD
Sirolimus—Dizziness—Epirubicin—hematologic cancer	2.27e-06	2.43e-05	CcSEcCtD
Sirolimus—Pruritus—Doxorubicin—hematologic cancer	2.25e-06	2.4e-05	CcSEcCtD
Sirolimus—Vomiting—Epirubicin—hematologic cancer	2.18e-06	2.34e-05	CcSEcCtD
Sirolimus—Nausea—Methotrexate—hematologic cancer	2.18e-06	2.33e-05	CcSEcCtD
Sirolimus—Diarrhoea—Doxorubicin—hematologic cancer	2.17e-06	2.33e-05	CcSEcCtD
Sirolimus—Rash—Epirubicin—hematologic cancer	2.16e-06	2.32e-05	CcSEcCtD
Sirolimus—Dermatitis—Epirubicin—hematologic cancer	2.16e-06	2.31e-05	CcSEcCtD
Sirolimus—Headache—Epirubicin—hematologic cancer	2.15e-06	2.3e-05	CcSEcCtD
Sirolimus—Dizziness—Doxorubicin—hematologic cancer	2.1e-06	2.25e-05	CcSEcCtD
Sirolimus—Nausea—Epirubicin—hematologic cancer	2.04e-06	2.18e-05	CcSEcCtD
Sirolimus—Vomiting—Doxorubicin—hematologic cancer	2.02e-06	2.16e-05	CcSEcCtD
Sirolimus—Rash—Doxorubicin—hematologic cancer	2e-06	2.14e-05	CcSEcCtD
Sirolimus—Dermatitis—Doxorubicin—hematologic cancer	2e-06	2.14e-05	CcSEcCtD
Sirolimus—Headache—Doxorubicin—hematologic cancer	1.99e-06	2.13e-05	CcSEcCtD
Sirolimus—Nausea—Doxorubicin—hematologic cancer	1.89e-06	2.02e-05	CcSEcCtD
Sirolimus—CYP3A7—Metabolism—MTHFR—hematologic cancer	8.23e-07	1.31e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—EP300—hematologic cancer	8.23e-07	1.31e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ENO2—hematologic cancer	8.23e-07	1.31e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PIK3R1—hematologic cancer	8.2e-07	1.31e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CDKN1B—hematologic cancer	8.15e-07	1.3e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—HRAS—hematologic cancer	8.08e-07	1.29e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—IL6—hematologic cancer	8.05e-07	1.28e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—HRAS—hematologic cancer	8.04e-07	1.28e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—hematologic cancer	8.03e-07	1.28e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PIK3CB—hematologic cancer	8.02e-07	1.28e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—FHL2—hematologic cancer	8.02e-07	1.28e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL1B—hematologic cancer	8.01e-07	1.28e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CD4—hematologic cancer	8.01e-07	1.28e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—SRC—hematologic cancer	8e-07	1.27e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—FGFR3—hematologic cancer	7.98e-07	1.27e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—MAPK3—hematologic cancer	7.98e-07	1.27e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GSTT1—hematologic cancer	7.98e-07	1.27e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL2—hematologic cancer	7.98e-07	1.27e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—JAK2—hematologic cancer	7.97e-07	1.27e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	7.91e-07	1.26e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MAPK14—hematologic cancer	7.9e-07	1.26e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—AGRN—hematologic cancer	7.87e-07	1.25e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—SDC1—hematologic cancer	7.8e-07	1.24e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—VEGFA—hematologic cancer	7.79e-07	1.24e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MDM2—hematologic cancer	7.78e-07	1.24e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—KRAS—hematologic cancer	7.77e-07	1.24e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—MYC—hematologic cancer	7.76e-07	1.24e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—JUN—hematologic cancer	7.76e-07	1.24e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ESR1—hematologic cancer	7.75e-07	1.24e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	7.74e-07	1.23e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—TGFB1—hematologic cancer	7.74e-07	1.23e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—STAT3—hematologic cancer	7.72e-07	1.23e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—NRAS—hematologic cancer	7.7e-07	1.23e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—IL6—hematologic cancer	7.7e-07	1.23e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—HRAS—hematologic cancer	7.68e-07	1.22e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—FN1—hematologic cancer	7.66e-07	1.22e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MTOR—hematologic cancer	7.57e-07	1.21e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PIK3CB—hematologic cancer	7.57e-07	1.21e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—BAD—hematologic cancer	7.57e-07	1.21e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NFKBIA—hematologic cancer	7.57e-07	1.21e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3CG—hematologic cancer	7.54e-07	1.2e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CDKN1B—hematologic cancer	7.53e-07	1.2e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CDKN1A—hematologic cancer	7.52e-07	1.2e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PTEN—hematologic cancer	7.51e-07	1.2e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NOTCH1—hematologic cancer	7.5e-07	1.19e-05	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	7.47e-07	1.19e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—HMMR—hematologic cancer	7.46e-07	1.19e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—IDH2—hematologic cancer	7.46e-07	1.19e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—AKT1—hematologic cancer	7.43e-07	1.18e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MAPK3—hematologic cancer	7.37e-07	1.17e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IL6—hematologic cancer	7.35e-07	1.17e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—MAPK8—hematologic cancer	7.34e-07	1.17e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CD80—hematologic cancer	7.34e-07	1.17e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3CG—hematologic cancer	7.33e-07	1.17e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KIT—hematologic cancer	7.33e-07	1.17e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GSTP1—hematologic cancer	7.33e-07	1.17e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PTPN11—hematologic cancer	7.2e-07	1.15e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MYC—hematologic cancer	7.17e-07	1.14e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—KRAS—hematologic cancer	7.17e-07	1.14e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—EP300—hematologic cancer	7.16e-07	1.14e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TGFB1—hematologic cancer	7.15e-07	1.14e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—PIK3CA—hematologic cancer	7.14e-07	1.14e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—AKT1—hematologic cancer	7.13e-07	1.14e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CDKN1B—hematologic cancer	7.1e-07	1.13e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—AKT1—hematologic cancer	7.1e-07	1.13e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ARNTL—hematologic cancer	7.01e-07	1.12e-05	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—ALB—hematologic cancer	6.99e-07	1.11e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CREBBP—hematologic cancer	6.99e-07	1.11e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CREB1—hematologic cancer	6.98e-07	1.11e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—SRC—hematologic cancer	6.96e-07	1.11e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CASP3—hematologic cancer	6.96e-07	1.11e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL2—hematologic cancer	6.95e-07	1.11e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CDKN1A—hematologic cancer	6.95e-07	1.11e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ABCB1—hematologic cancer	6.94e-07	1.11e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PTEN—hematologic cancer	6.93e-07	1.1e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3CG—hematologic cancer	6.92e-07	1.1e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—BRAF—hematologic cancer	6.89e-07	1.1e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCL2—hematologic cancer	6.83e-07	1.09e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ACP5—hematologic cancer	6.82e-07	1.09e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CA9—hematologic cancer	6.82e-07	1.09e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL6R—hematologic cancer	6.81e-07	1.08e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CREBBP—hematologic cancer	6.8e-07	1.08e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—AKT1—hematologic cancer	6.78e-07	1.08e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCND1—hematologic cancer	6.78e-07	1.08e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—JUN—hematologic cancer	6.76e-07	1.08e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GSTM1—hematologic cancer	6.74e-07	1.07e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—NCOR1—hematologic cancer	6.74e-07	1.07e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NCOR2—hematologic cancer	6.73e-07	1.07e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—STAT3—hematologic cancer	6.71e-07	1.07e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—NRAS—hematologic cancer	6.7e-07	1.07e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CD44—hematologic cancer	6.63e-07	1.06e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—NQO1—hematologic cancer	6.63e-07	1.06e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3CD—hematologic cancer	6.63e-07	1.06e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—KRAS—hematologic cancer	6.63e-07	1.06e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—EP300—hematologic cancer	6.61e-07	1.05e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HRAS—hematologic cancer	6.6e-07	1.05e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—PIK3CA—hematologic cancer	6.59e-07	1.05e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CDKN1A—hematologic cancer	6.55e-07	1.04e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ALB—hematologic cancer	6.54e-07	1.04e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PTEN—hematologic cancer	6.54e-07	1.04e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MAP2K1—hematologic cancer	6.49e-07	1.03e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3CD—hematologic cancer	6.44e-07	1.03e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—SRC—hematologic cancer	6.43e-07	1.02e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CREBBP—hematologic cancer	6.41e-07	1.02e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—MAPK3—hematologic cancer	6.41e-07	1.02e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—IDH1—hematologic cancer	6.41e-07	1.02e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MAPK8—hematologic cancer	6.4e-07	1.02e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTO1—hematologic cancer	6.34e-07	1.01e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—TXN—hematologic cancer	6.34e-07	1.01e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ABCC3—hematologic cancer	6.34e-07	1.01e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL6—hematologic cancer	6.32e-07	1.01e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYCS—hematologic cancer	6.27e-07	9.99e-06	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3R1—hematologic cancer	6.26e-07	9.97e-06	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EP300—hematologic cancer	6.24e-07	9.93e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—HSP90AA1—hematologic cancer	6.23e-07	9.93e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SPHK1—hematologic cancer	6.2e-07	9.88e-06	CbGpPWpGaD
Sirolimus—MTOR—Disease—STAT3—hematologic cancer	6.2e-07	9.87e-06	CbGpPWpGaD
Sirolimus—MTOR—Disease—NRAS—hematologic cancer	6.18e-07	9.85e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—FGF2—hematologic cancer	6.17e-07	9.83e-06	CbGpPWpGaD
Sirolimus—FGF2—Disease—HRAS—hematologic cancer	6.1e-07	9.71e-06	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PIK3CA—hematologic cancer	6.09e-07	9.7e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3R1—hematologic cancer	6.08e-07	9.69e-06	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3CD—hematologic cancer	6.08e-07	9.69e-06	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SRC—hematologic cancer	6.06e-07	9.66e-06	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ALB—hematologic cancer	6e-07	9.56e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—UGT1A1—hematologic cancer	5.96e-07	9.49e-06	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—MTHFR—hematologic cancer	5.95e-07	9.48e-06	CbGpPWpGaD
Sirolimus—MTOR—Disease—MAPK3—hematologic cancer	5.92e-07	9.43e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—JAK2—hematologic cancer	5.91e-07	9.42e-06	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—VEGFA—hematologic cancer	5.91e-07	9.41e-06	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—hematologic cancer	5.89e-07	9.38e-06	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—STAT3—hematologic cancer	5.85e-07	9.32e-06	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NRAS—hematologic cancer	5.83e-07	9.29e-06	CbGpPWpGaD
Sirolimus—FGF2—Disease—IL6—hematologic cancer	5.83e-07	9.29e-06	CbGpPWpGaD
Sirolimus—FGF2—Immune System—AKT1—hematologic cancer	5.83e-07	9.28e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CRABP1—hematologic cancer	5.8e-07	9.24e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SLC22A1—hematologic cancer	5.8e-07	9.24e-06	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3CB—hematologic cancer	5.78e-07	9.2e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MDM2—hematologic cancer	5.77e-07	9.19e-06	CbGpPWpGaD
Sirolimus—MTOR—Immune System—KRAS—hematologic cancer	5.76e-07	9.18e-06	CbGpPWpGaD
Sirolimus—MTOR—Disease—MYC—hematologic cancer	5.76e-07	9.17e-06	CbGpPWpGaD
Sirolimus—MTOR—Disease—TGFB1—hematologic cancer	5.75e-07	9.15e-06	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3R1—hematologic cancer	5.74e-07	9.15e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ALOX5—hematologic cancer	5.65e-07	9e-06	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HRAS—hematologic cancer	5.63e-07	8.97e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3CB—hematologic cancer	5.62e-07	8.95e-06	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MAPK3—hematologic cancer	5.59e-07	8.9e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GSTP1—hematologic cancer	5.53e-07	8.81e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NUP98—hematologic cancer	5.47e-07	8.72e-06	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MYC—hematologic cancer	5.43e-07	8.66e-06	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TGFB1—hematologic cancer	5.42e-07	8.64e-06	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL6—hematologic cancer	5.39e-07	8.59e-06	CbGpPWpGaD
Sirolimus—FGF2—Disease—AKT1—hematologic cancer	5.38e-07	8.57e-06	CbGpPWpGaD
Sirolimus—MTOR—Disease—KRAS—hematologic cancer	5.32e-07	8.48e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ADCY7—hematologic cancer	5.31e-07	8.46e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NCOA3—hematologic cancer	5.31e-07	8.46e-06	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3CB—hematologic cancer	5.3e-07	8.44e-06	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PIK3CA—hematologic cancer	5.3e-07	8.43e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NUP214—hematologic cancer	5.28e-07	8.4e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CDKN1B—hematologic cancer	5.27e-07	8.39e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ABCG2—hematologic cancer	5.17e-07	8.23e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—MTR—hematologic cancer	5.17e-07	8.23e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CASP3—hematologic cancer	5.17e-07	8.23e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL2—hematologic cancer	5.16e-07	8.22e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—NCOR1—hematologic cancer	5.08e-07	8.09e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GSTM1—hematologic cancer	5.08e-07	8.09e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ENO2—hematologic cancer	5.07e-07	8.07e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCND1—hematologic cancer	5.03e-07	8.01e-06	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—KRAS—hematologic cancer	5.02e-07	8e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—JUN—hematologic cancer	5.02e-07	7.99e-06	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3CG—hematologic cancer	5e-07	7.97e-06	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PTEN—hematologic cancer	4.99e-07	7.95e-06	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—AKT1—hematologic cancer	4.97e-07	7.92e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTT1—hematologic cancer	4.92e-07	7.83e-06	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HRAS—hematologic cancer	4.9e-07	7.8e-06	CbGpPWpGaD
Sirolimus—MTOR—Disease—PIK3CA—hematologic cancer	4.89e-07	7.79e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CDKN1A—hematologic cancer	4.86e-07	7.75e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PTEN—hematologic cancer	4.85e-07	7.73e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SDC1—hematologic cancer	4.8e-07	7.65e-06	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—EP300—hematologic cancer	4.76e-07	7.58e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MAPK8—hematologic cancer	4.75e-07	7.56e-06	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL6—hematologic cancer	4.69e-07	7.47e-06	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CREBBP—hematologic cancer	4.64e-07	7.39e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EP300—hematologic cancer	4.63e-07	7.37e-06	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PIK3CA—hematologic cancer	4.61e-07	7.35e-06	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PTEN—hematologic cancer	4.58e-07	7.3e-06	CbGpPWpGaD
Sirolimus—MTOR—Disease—HRAS—hematologic cancer	4.52e-07	7.2e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SRC—hematologic cancer	4.5e-07	7.17e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—MTHFR—hematologic cancer	4.49e-07	7.15e-06	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—hematologic cancer	4.46e-07	7.11e-06	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3CD—hematologic cancer	4.4e-07	7e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—VEGFA—hematologic cancer	4.38e-07	6.98e-06	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—EP300—hematologic cancer	4.37e-07	6.96e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—STAT3—hematologic cancer	4.34e-07	6.91e-06	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ALB—hematologic cancer	4.34e-07	6.91e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NRAS—hematologic cancer	4.33e-07	6.9e-06	CbGpPWpGaD
Sirolimus—MTOR—Disease—IL6—hematologic cancer	4.33e-07	6.9e-06	CbGpPWpGaD
Sirolimus—MTOR—Immune System—AKT1—hematologic cancer	4.33e-07	6.89e-06	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HRAS—hematologic cancer	4.27e-07	6.8e-06	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3R1—hematologic cancer	4.15e-07	6.61e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MAPK3—hematologic cancer	4.15e-07	6.6e-06	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL6—hematologic cancer	4.09e-07	6.51e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CD44—hematologic cancer	4.09e-07	6.51e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NQO1—hematologic cancer	4.09e-07	6.51e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MYC—hematologic cancer	4.03e-07	6.42e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TGFB1—hematologic cancer	4.02e-07	6.41e-06	CbGpPWpGaD
Sirolimus—MTOR—Disease—AKT1—hematologic cancer	3.99e-07	6.36e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYCS—hematologic cancer	3.87e-07	6.16e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	3.84e-07	6.12e-06	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3CB—hematologic cancer	3.83e-07	6.1e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3CG—hematologic cancer	3.77e-07	6.01e-06	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—AKT1—hematologic cancer	3.77e-07	6e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KRAS—hematologic cancer	3.73e-07	5.94e-06	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3CA—hematologic cancer	3.52e-07	5.61e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CREBBP—hematologic cancer	3.5e-07	5.57e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3CA—hematologic cancer	3.42e-07	5.45e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTP1—hematologic cancer	3.41e-07	5.43e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3CD—hematologic cancer	3.32e-07	5.28e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—hematologic cancer	3.31e-07	5.28e-06	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PTEN—hematologic cancer	3.31e-07	5.27e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ALB—hematologic cancer	3.28e-07	5.22e-06	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3CA—hematologic cancer	3.23e-07	5.15e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ABCB1—hematologic cancer	3.23e-07	5.14e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HRAS—hematologic cancer	3.17e-07	5.05e-06	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—EP300—hematologic cancer	3.16e-07	5.03e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3R1—hematologic cancer	3.13e-07	4.99e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTM1—hematologic cancer	3.13e-07	4.99e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NCOR1—hematologic cancer	3.13e-07	4.99e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL6—hematologic cancer	3.03e-07	4.83e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3CB—hematologic cancer	2.89e-07	4.61e-06	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—AKT1—hematologic cancer	2.88e-07	4.58e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—AKT1—hematologic cancer	2.8e-07	4.45e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—MTHFR—hematologic cancer	2.77e-07	4.41e-06	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—AKT1—hematologic cancer	2.64e-07	4.2e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PTEN—hematologic cancer	2.5e-07	3.98e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—EP300—hematologic cancer	2.38e-07	3.8e-06	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3CA—hematologic cancer	2.34e-07	3.72e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3CG—hematologic cancer	2.33e-07	3.7e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CREBBP—hematologic cancer	2.16e-07	3.43e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3CD—hematologic cancer	2.04e-07	3.26e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ALB—hematologic cancer	2.02e-07	3.21e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.93e-07	3.07e-06	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—AKT1—hematologic cancer	1.91e-07	3.04e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.78e-07	2.84e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3CA—hematologic cancer	1.76e-07	2.81e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PTEN—hematologic cancer	1.54e-07	2.45e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—EP300—hematologic cancer	1.47e-07	2.34e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—AKT1—hematologic cancer	1.44e-07	2.29e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.09e-07	1.73e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—AKT1—hematologic cancer	8.87e-08	1.41e-06	CbGpPWpGaD
